Tabalumab

Drug Profile

Tabalumab

Alternative Names: Anti-BAFF MAb; Anti-BAFF monoclonal antibody; LY 2127399

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Multiple sclerosis; Renal failure; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2015 Eli Lilly terminates phase III trial in Systemic lupus erythematosus in USA, South Korea, Mexico and Puerto Rico due to lack of efficacy (NCT02041091)
  • 01 Aug 2015 Eli Lilly completes a phase I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Japan (IV) (NCT01556438)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top